Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2663MR)

This product GTTS-WQ2663MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2663MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11680MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ11776MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ5843MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ14858MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ5105MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ14035MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ9122MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ15983MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW